Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Valentina Vaira 5"'
Triple negative aggressive phenotype controlled by miR-135b and miR-365: new theranostics candidates
Autor:
Gloria Bertoli 1, 8, Claudia Cava 1, Fabio Corsi 2, 3, Francesca Piccotti 4, Cristina Martelli 5, Luisa Ottobrini 5, Valentina Vaira 5, 6, Isabella Castiglioni 1, 7
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
Scientific Reports
Scientific reports (Nature Publishing Group) 11 (2021): 6553. doi:10.1038/s41598-021-85746-w
info:cnr-pdr/source/autori:Gloria Bertoli 1,8*, Claudia Cava 1,8, Fabio Corsi 2,3, Francesca Piccotti 4, Cristina Martelli 5, Luisa Ottobrini 5, Valentina Vaira 5,6 & Isabella Castiglioni 1,7/titolo:Triple negative aggressive phenotype controlled by miR-135b and miR-365: new theranostics candidates/doi:10.1038%2Fs41598-021-85746-w/rivista:Scientific reports (Nature Publishing Group)/anno:2021/pagina_da:6553/pagina_a:/intervallo_pagine:6553/volume:11
Scientific Reports
Scientific reports (Nature Publishing Group) 11 (2021): 6553. doi:10.1038/s41598-021-85746-w
info:cnr-pdr/source/autori:Gloria Bertoli 1,8*, Claudia Cava 1,8, Fabio Corsi 2,3, Francesca Piccotti 4, Cristina Martelli 5, Luisa Ottobrini 5, Valentina Vaira 5,6 & Isabella Castiglioni 1,7/titolo:Triple negative aggressive phenotype controlled by miR-135b and miR-365: new theranostics candidates/doi:10.1038%2Fs41598-021-85746-w/rivista:Scientific reports (Nature Publishing Group)/anno:2021/pagina_da:6553/pagina_a:/intervallo_pagine:6553/volume:11
Triple negative breast cancer (TNBC) accounts for about a fifth of all breast cancers and includes a diverse group of cancers. The heterogeneity of TNBC and the lack of target receptors on the cell surface make it difficult to develop specific therap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a590116de06fe91ff29cc6f7311c6a45
https://doaj.org/article/55a1477ce51945d6b0c6006989afd3e2
https://doaj.org/article/55a1477ce51945d6b0c6006989afd3e2
Autor:
Silvia Valtorta 1, 2, 3, 4, Alessia Lo Dico 5, Isabella Raccagni 1, Daniela Gaglio 2, Sara Belloli 2, Letterio S. Politi 6, 7, 8, Cristina Martelli 5, Cecilia Diceglie 5, 1, Marcella Bonanomi 4, Giulia Ercoli 9, Valentina Vaira 5, 9, Luisa Ottobrini 2, 5, Rosa Maria Moresco 1
Publikováno v:
Oncotarget (2017).
info:cnr-pdr/source/autori:Silvia Valtorta 1,2,3,4,*, Alessia Lo Dico 5,*, Isabella Raccagni 1,2,3,4, Daniela Gaglio 2,4, Sara Belloli 2,3,4, Letterio S. Politi 6,7,8, Cristina Martelli 5, Cecilia Diceglie 5,1, Marcella Bonanomi 4, Giulia Ercoli 9, Valentina Vaira 5,9, Luisa Ottobrini 2,5,* and Rosa Maria Moresco 1,2,3,4,*/titolo:Metformin and Temozolomide, a synergic option to overcome resistance in glioblastoma multiforme models/doi:/rivista:Oncotarget/anno:2017/pagina_da:/pagina_a:/intervallo_pagine:/volume
info:cnr-pdr/source/autori:Silvia Valtorta 1,2,3,4,*, Alessia Lo Dico 5,*, Isabella Raccagni 1,2,3,4, Daniela Gaglio 2,4, Sara Belloli 2,3,4, Letterio S. Politi 6,7,8, Cristina Martelli 5, Cecilia Diceglie 5,1, Marcella Bonanomi 4, Giulia Ercoli 9, Valentina Vaira 5,9, Luisa Ottobrini 2,5,* and Rosa Maria Moresco 1,2,3,4,*/titolo:Metformin and Temozolomide, a synergic option to overcome resistance in glioblastoma multiforme models/doi:/rivista:Oncotarget/anno:2017/pagina_da:/pagina_a:/intervallo_pagine:/volume
Glioblastoma multiforme (GBM) is the most aggressive primary brain tumor with poor survival. Cytoreduction in association with radiotherapy and temozolomide (TMZ) is the standard therapy, but response is heterogeneous and life expectancy is limited.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=cnr_________::7ffbe54f58bfb27b307ca2d8e493dcce
https://publications.cnr.it/doc/379984
https://publications.cnr.it/doc/379984
